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Introduction
Flushing procedures to clean intravenous (IV) tubing and 
catheters are common practice whenever solutions are admin-
istered intravenously.1 IV tubing, which connects an IV bag 
or syringe to the patient’s IV access, is flushed to make sure 
all drugs present in the tubing are delivered into the blood-
stream of the patient.2 IV catheters need to be flushed and 
locked at the end of infusion to clear or prevent obstruction 
and thrombus formation, or to reduce bacterial colonization 
during the period when the catheter is idle.3,4 Normal saline 
(NS; NaCl 0.9%) and glucose 5% (G5) are commonly used as 
a flushing fluids as they are compatible with many IV drugs.5
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Abstract
Background: Administering a separator fluid between incompatible solutions can optimize the use of intravenous 
lumens. Factors affecting the required separator fluid volume to safely separate incompatible solutions are unknown.
Methods: An intravenous tube (2-m, 2-mL, 6-French) containing methylene blue dye was flushed with separator fluid 
until a methylene blue concentration ⩽2% from initial was reached. Independent variables were administration rate, 
dye solvent (glucose 5% and NaCl 0.9%), and separator fluid. In the second part of the study, methylene blue, separator 
fluid, and eosin yellow were administered in various administration profiles using 2- and 4-mL (2 × 2 m, 4-mL, 6-French) 
intravenous tubes.
Results: Neither administration rate nor solvent affected the separator fluid volume (p = 0.24 and p = 0.12, respectively). 
Glucose 5% as separator fluid required a marginally smaller mean ± SD separator fluid volume than NaCl 0.9% 
(3.64 ± 0.13 mL vs 3.82 ± 0.11 mL, p < 0.001). Using 2-mL tubing required less separator fluid volume than 4-mL tubing 
for methylene blue (3.89 ± 0.57 mL vs 4.91 ± 0.88 mL, p = 0.01) and eosin yellow (4.41 ± 0.56 mL vs 5.63 ± 0.15 mL, 
p < 0.001). Extended tubing required less separator fluid volume/mL of tubing than smaller tubing for both methylene 
blue (2 vs 4 mL, 1.54 ± 0.22 vs 1.10 ± 0.19, p < 0.001) and eosin yellow (2 vs 4 mL, 1.75 ± 0.22 vs 1.25 ± 0.03, p < 0.001).
Conclusion: The separator fluid volume was neither affected by the administration rate nor by solvent. Glucose 5% 
required a marginally smaller separator fluid volume than NaCl 0.9%, however its clinical impact is debatable. A larger 
intravenous tubing volume requires a larger separator fluid volume. However, the ratio of separator fluid volume to the 
tubing’s volume decreases as the tubing volume increases.
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Another function of flushing is to separate two incom-
patible drug solutions that are sequentially administered. A 
separator fluid (SF) serves to avoid the contact of the 
incompatible solutions before they reach the bloodstream. 
When two drug solutions are physically or chemically 
incompatible, precipitation or inactivation may occur 
when they are mixed.5 When incompatible IV solutions 
must be administered continuously, a common way to 
address this problem is the use of multiple catheters or 
multi-lumen catheters that allow for a separated flow of 
each solution.6,7 However, even with such systems, the 
number of incompatible solutions may still exceed the 
number of available lumens.
In such a case sandwiching a SF between the incompati-
ble solutions facilitates the use of a single lumen for the 
administration of these solutions.8 When administering a SF 
between incompatible solutions it is important to know what 
minimal separator fluid volume (SFV) is required so that no 
relevant interaction takes place between the constituents of 
these solutions.
This volume must be sufficient to avoid mixing, but 
should not be excessive as patients may have a limited fluid 
intake regimen.9,10 The administration rate, drug solvent, 
choice of SF, and IV tubing volume may also be factors 
affecting the required SFV.11–13 However, to our knowledge 
there is no literature on the requirements of flushing.
In this study we aimed to investigate whether and how 
the administration rate, drug solvent, choice of SF, its 
administration rate, and the IV tubing volume affects the 
SFV required for the safe separation of incompatible 




Part 1: influence of administration rate, solvent, and SF. In this 
part of the study we investigated to which extent the admin-
istration rate, solvent, and SF affected the required SFV. 
Figure 1. (a) Experimental setup used to investigate whether and how the administration rate, solvent, and separator fluid (SF) 
affect the required SF volume (SFV). A 2-m (2-mL) IV tube runs between the three-way stopcock and the fraction collector. (b) 
Experimental setup used to investigate whether and how IV line volume affects the required SFV in different administration profiles. 
MB: methylene blue, EY: eosin yellow. Depending on the administration profile, either a 2-m (2-mL) IV tube or 2 × 2 m tubes (4-mL) 
run between the stopcocks and the fraction collector.
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The experimental setup is shown in Figure 1(a). Three dif-
ferent rates were used: 50, 100, and 200 mL/h.
Quantitative measurements were carried out using 
ultraviolet−visible (UV-Vis) spectrophotometry, too high 
concentrations of methylene blue (MB) would result in 
absorption readings that do not reliably allow detection of 
concentration differences due to saturation of the measur-
ing cell. Therefore, we chose concentrations that resulted 
in calibration curves for both dyes in the linear part of the 
calibration curve. For MB and eosin yellow (EY) this 
resulted in maximum concentrations of 40 and 75 mg/L, 
respectively.
MB solutions were prepared in a concentration of 
40 mg/L, using NS as solvent in one solution and G5 in the 
other. The SF was either NS or G5. This resulted in 3 × 2 × 2 
(administration rate × solvent × SF) combinations.
A 2-mL (2-m, 6-French) IV tube was completely filled 
with MB solution. Subsequently an infusion pump con-
taining a syringe with SF was started at one of three admin-
istration rates. Samples of 0.67 mL were collected in tubes 
using a fraction collector. Administration of SF was 
stopped after 10 mL of SF was administered. Collected 
samples were transferred from the tubes onto a 96-well 
plate. This process was performed 3 times for each unique 
combination of administration rate, solvent, and SF.
For the determination of MB concentrations a calibration 
curve was made using different dilutions of MB, samples at 
each concentration were transferred in duplicate onto a 
96-well plate. Absorption of MB was measured at 668 nm.
Part 2: influence of system volume in different administration 
profiles. The experimental setup is shown in Figure 1(b). 
G5 was selected as solvent and NS was selected as SF 
for the second part of the study to comply with clinical 
practice in our intensive care unit (ICU). The goal of this 
part of the study was to investigate how the IV tubing vol-
ume affected the required volume of SF in different admin-
istration profiles. The administration rate was kept constant 
at 50 mL/h. EY was used as a secondary dye, and was dis-
solved in G5 to a concentration of 75 mg/L. The EY con-
centration was determined using the same procedure as 
with MB. Either a 2-mL (2-m, 6-French) IV tube was used, 
or two 2-mL IV tubes were connected to create a combined 
IV tubing volume of 4 mL.
An important concept is the shared infusion tubing, 
which consists of the tubing and connectors that are shared 
by all fluids. The three-way stopcocks and the IV tubing 
that runs between the stopcocks and the fraction collector 
are all considered part of the shared infusion tubing. The 
volume of the shared infusion tubing is called the shared 
infusion volume (SIV).
The administration profiles were coded as shown in 
Figure 2. The coding consists of three parts: IV tubing vol-
ume, a start condition that describes the content of the IV 
tubing before the start of the administration profile, and the 
order in which MB, SF, and EY are administered with the 
corresponding volumes.
For example, in Figure 2, 2-mL tubing is used which is 
filled with 2 mL of MB (MB2) before the start of the exper-
iment. At the start of the experiment, first 5 mL of SF (SF5) 
is administered, followed by 2 mL of EY (EY2), and 9 mL 
of SF (SF9). It must be noted that in profiles where the tub-
ing is filled with MB at the start, the total volume of MB is 
equal to the SIV, including the three-way stopcocks that 
are part of the SIV. In profiles with 2 or 4 mL tubing, the 
SIV is 2.52 or 4.52 mL, respectively.
Three types of administration profiles were created for 
the two tubing volumes. One profile type started with the 
Figure 2. The coding of administration profiles. The three segments (separated by a horizontal line), respectively, represent the 
IV tubing volume in mL, pre-start condition, and the administration sequence. MB: methylene blue, EY: eosin yellow, SF: separator 
fluid. Numbers trailing the substance indicators in subscript indicate the volume of the indicated substance in mL.
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tubing completely filled with MB, followed by NS, EY, 
and NS (2-MB2-NS5EY2 and 4-MB4-NS5EY4NS9). The 
two other types started with the tubing filled with NS, 
after which MB, NS, EY, and NS were administered. In 
these two profiles the administered volumes of MB and 
EY were both 25% (2-NS2-MB0.5NS5EY0.5NS9 and 4-NS4-
MB1NS5EY1NS9), or both 50% of the tubing volume 
(2-NS2-MB1NS5EY1NS9 and 4-NS4-MB2NS5EY2NS9). 
In two profiles (2-NS2-MB1NS5EY1NS9 and 4-NS4-
MB1NS5EY1NS9) the administration sequences were 
identical, only the tubing volume differed.
Each profile was administered three times. Infusion 
pumps were controlled from a laptop using custom soft-
ware that allowed predefining administration sequences 
for automatic execution. The collection of samples and 
calibration procedures were identical to the first part of the 
study, with the addition of a calibration curve for EY. EY’s 
absorption was measured at 524 nm.
Determination of SFV. We arbitrarily chose a concentration 
of 2% relative to the original MB and EY solutions as the 
cut-off point to determine the minimal required SFV. We 
assumed that in clinical practice no meaningful chemical 
interaction would occur at this cut-off point.
GraphPad Prism14 was used to determine the SFV by 
curve fitting starting from the data point with the high-
est measured concentration (Figure 3). For part 1 of the 
study, nonlinear regression was applied in GraphPad 
Prism using the “log (inhibitor) vs normalized response–
variable slope” setting. In part 2, nonlinear regression 
was applied using the “plateau followed by one phase 
decay” setting. The cut-off concentration was entered 
into the resulting equation to obtain the corresponding 
SFV.
Materials
Fluids used in the experiments were NS, a 0.9% sodium 
chloride solution in water, and G5, a 5% glucose solution 
in water. Both were obtained from Baxter (The 
Netherlands). MB and EY were obtained from Merck 
(Germany).
The experimental setup consisted of three Alaris Asena 
GH syringe pumps (Carefusion, UK), a Pharmacia LKB 
FRAC-200 fraction collector (Pharmacia, Sweden), a 
Hewlett-Packard Probook 6560b laptop (Hewlett-Packard, 
USA), a StarTech ICUSB2324X USB to serial adapter 
(StarTech, UK), three generic RS232 cables, 50-mL BD 
Plastipak syringes (Becton-Dickinson, USA), Steritex 3W 
three-way stopcocks (Codan, Denmark), Vygon V-Green IV 
(2-m length, 2-mL volume, 6-French outer diameter) IV 
tubes (Vygon, France), and generic round-bottom polysty-
rene tubes. Custom software was written in Java (Oracle 
Corporation, USA) for external coordinated control of the 
infusion pumps using their serial communication protocol.15
UV-Vis measurements were performed using a 
SYNERGY-HT multiwell plate reader (BioTek Instruments 
Incorporated, USA), which used Corning Costar 3596 
96-well plates (Corning Incorporated, USA).
Statistical analysis
IBM SPSS Statistics was used for the statistical analysis.16 
Statistical significance was determined at a two-sided 
p-value <0.05.
In the first part of the study, we investigated the influ-
ence of administration rate, dye solvent, and SF on the SFV. 
Group differences for administration rate were assessed 
using a one-way analysis of variance (ANOVA). If the 
ANOVA result was statistically significant, post hoc pair-
wise comparisons with Bonferroni correction were per-
formed. For the variables dye solvent and SF, a Student’s t 
test was performed.
In the second part of the study, SFV required to flush 
MB and EY from the IV tubing are abbreviated as SFVMB 
and SFVEY, repectively. The ratio of SFVMB and the SIV 
(RatioMB/SIV) was calculated by dividing SFVMB by the 
SIV. A RatioMB/SIV of 2 indicates the SFV required to flush 
MB from the IV tubing is twice the SIV. In a similar fash-
ion, RatioEY/SIV was calculated. Statistically significant dif-
ferences between groups were assessed using the Student’s 
t test.
Results
SFVs for each combination of administration rate, solvent, 
and SF in part 1 of the experiment are listed in Table 1. 
There was no statistically significant relation between 
administration rate and SFV as determined by a one-way 
ANOVA (F(2.33) = 1.50, p = 0.24). The choice of solvent 
Figure 3. Determination of the SFV at 2% of the initial 
dye concentration (dashed line). Sample data (circles) were 
transformed to a logarithmic scale to enable curve fitting 
(continuous line). The resulting equation was used to obtain 
the log mL SFV at the 2% concentration, which in turn was 
transformed back to mL.
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had no statistically significant relation with SFV (G5 vs 
NS mean ± standard deviation (SD), 3.69 ± 0.10 mL vs 
3.77 ± 0.17 mL, p = 0.12). Using G5 as SF required less 
SFV than NS (G5 vs NS mean ± SD, 3.64 ± 0.13 mL vs 
3.82 ± 0.11 mL, p < 0.001). The 95% confidence intervals 
(CI) for SFs G5 and NS were [3.58−3.71] and [3.77−3.88], 
respectively.
For experimental part 2, the time courses of concentra-
tions of the six administration profiles can be found 
in Supplemental Figures S1−S6. Overall differences 
between profiles using 2 and 4 mL IV tubes are displayed 
in Table 2. SFVMB was smaller than SFVEY overall (SFVMB 
Table 1. Separator fluid volume for each combination of solvent, separator fluid, and administration rate.
Solvent Separator fluid Rate (mL/h) Separator fluid volume
Mean ± SD (mL)
NS NS 50 3.80 ± 0.00
100 3.93 ± 0.06
200 3.93 ± 0.12
G5 50 3.60 ± 0.00
100 3.63 ± 0.06
200 3.73 ± 0.29
G5 NS 50 3.73 ± 0.06
100 3.77 ± 0.06
200 3.77 ± 0.12
G5 50 3.57 ± 0.06
100 3.70 ± 0.10
200 3.63 ± 0.06
SD: standard deviation; NS: normal saline (0.9% NaCl); G5: glucose 5% solution in water.
Table 2. Overall differences in profiles using 2 and 4 mL tubing volume.
IV tubing/shared infusion volume 2 mL/2.52 mL (n = 9) 4 mL/4.52 mL (n = 9) pa
SFVMB mean ± SD 3.89 ± 0.57 4.91 ± 0.88 0.01
SFVEY mean ± SD 4.41 ± 0.56 5.63 ± 0.15 <0.001
RatioMB/SIV mean ± SD 1.54 ± 0.22 1.09 ± 0.19 <0.001
RatioEY/SIV mean ± SD 1.75 ± 0.22 1.25 ± 0.03 <0.001
SD: standard deviation; SFVX: separator fluid volume required to clear the IV tubing of solution X; RatioX/SIV: ratio of SFVX and the shared infusion 
volume; EY: eosin yellow; MB: methylene blue.
aStudent’s t test.









2-MB2-NS5EY2NS9 4.52 ± 0.16 5.06 ± 0.16 1.79 ± 0.06 2.01 ± 0.06
2-NS2-MB0.5NS5EY0.5NS9 3.27 ± 0.06 3.90 ± 0.36 1.30 ± 0.02 1.55 ± 0.14
2-NS2-MB1NS5EY1NS9 3.89 ± 0.27 4.29 ± 0.19 1.54 ± 0.11 1.70 ± 0.07
4-MB4-NS5EY4NS9 6.04 ± 0.27 5.70 ± 0.16 1.34 ± 0.06 1.26 ± 0.04
4-NS4-MB1NS5EY1NS9 4.19 ± 0.13 5.67 ± 0.06 0.93 ± 0.03 1.25 ± 0.01
4-NS4-MB2NS5EY2NS9 4.51 ± 0.17 5.54 ± 0.21 1.00 ± 0.04 1.22 ± 0.05
Note that normal saline was used as separator fluid in all profiles. SFVX: separator fluid volume required to clear the IV tubing of solution X; RatioX/
SIV: ratio of SFVX and the shared infusion volume; EY: eosin yellow; MB: methylene blue; NS: normal saline.
vs SFVEY: mean ± SD, 4.40 ± 0.89 mL vs 5.02 ± 0.74 mL, 
p < 0.001). RatioMB/SIV was smaller than RatioEY/SIV over-
all (RatioMB/SIV vs RatioEY/SIV: mean ± SD, 1.31 ± 0.31 vs 
1.50 ± 0.30, p < 0.001). Table 3 lists the SFVMB, SFVEY, 
RatioMB/SIV, and RatioEY/SIV values of the individual admin-
istration profiles.
Discussion
In our first experiment, we investigated the impact of 
administration rate, solvent, and SF on the SFV. We found 
a marginal difference between using G5 and NS as SF, but 
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found no advantage in the choice of solvent or administra-
tion rate. In our second experiment, we administered sev-
eral simulated sequential drug profiles where drug solutions 
were separated by a SF. We found that extending the IV 
tubing using an additional IV tube, required a larger SFV. In 
this case, with the inner and outer diameter of the tubing 
remaining the same, both the tubing’s length and volume 
were doubled. Per mL of tubing volume we found that the 
required SFV was smaller when longer tubing was used. To 
our knowledge, this study is the first to investigate the fac-
tors contributing to the requirements of the SFV.
The Royal College of Nursing1 recommends using at 
least twice the priming volume of the device for flushing, 
but does not provide any empirical data to support their 
recommendation. Another publication recommends a 
flushing volume of 3−5 mL with no further explanation.17 
One study provided empirical evidence suggesting that 
flushing twice the priming volume of a Soluset IV system 
(Abbott Laboratories, USA) is sufficient to deliver >95% 
of the preceding medication.18 However, in this study only 
volumetric infusions were taken into account, whereas 
syringe pumps that commonly administer more concen-
trated drug solutions through narrower tubing systems 
may require different volumes. In our study, we found that 
for an IV tubing system with a SIV of 2.52 mL, the mean 
SFVMB was 3.89 mL and the mean SFVEY was 4.91 mL, 
rendering a RatioMB/SIV of 1.5 and a RatioEY/SIV of 2.0. 
Hence, flushing the system with a SFV that is at least twice 
the priming volume as a rule of thumb seems reasonable to 
have sufficient separation between incompatible drugs 
delivered one after the other.
In part 1 of this study we found that when G5 is used as 
a SF, a marginally smaller SFV is required than using NS. 
One explanation might be that G5 is more viscous than NS 
and therefore slightly more effective as a SF. An alterna-
tive explanation may attribute this finding to artifacts in 
the study. At the start of each experiment, priming of the 
tubing and starting both the pump and the fraction collec-
tor had to be performed manually. Therefore, the differ-
ence between G5 and NS may also be caused by human 
variability. Although statistically significant, a difference 
between means of only 0.2 mL has little to no impact in 
clinical practice.
Overall, profiles with longer tubing also required a 
larger SFV (Table 2). For example, in profile 4-MB4-
NS5EY4NS9 both the IV tubing lengths (and volumes) and 
the administered volumes of MB and EY are twice that of 
profile 2-MB2-NS5EY2NS9 (Table 3). As there is more MB 
and EY present in the IV tubing in 4-MB4-NS5EY4NS9, it 
is not surprising that a larger SFVMB and SFVEY are 
required compared to 2-MB2-NS5EY2NS9. When compar-
ing 2-NS2-MB1NS5EY1NS9 to 4-NS4-MB1NS5EY1NS9, 
the IV tubing length differs, but the administration 
sequence is the same. Again, the SFVs are larger with 
longer tubing. This finding may also be explained by 
Poiseuille flow, which describes the flow through a cylin-
drical tube where the cross-section of the tube can be 
divided into laminae (circular layers of fluid).19,20 Each 
lamina has its own velocity. The outer lamina will have a 
lower velocity than the middle lamina due to friction with 
the tubing wall. Assuming Poiseuille flow takes place 
within the IV tubing, there will be a difference when the 
middle and outer lamina reach the end of the tube. In 
longer tubing, the contact time with the tubing wall is 
longer, hence a greater difference in velocities of the lam-
ina and therefore more dispersion will occur. In that case it 
can be expected that the dye can be measured for a longer 
period of time, which is illustrated in Supplemental 
Figure S7. Supplemental Table S8 lists the timespans in 
which MB and EY were measured at the end of the tubing 
at a concentration >2%. When the same dye volume is 
administered at the same rate, but through longer tubing 
(e.g. when comparing 2-NS2-MB1NS5EY1NS9 to 4-NS4-
MB1NS5EY1NS9), the dye is measured for a longer period 
of time. This observation is compatible with more disper-
sion and that diffusion has taken place, however a larger 
sample size is required before any conclusions can be 
drawn. Overall, RatioMB/SIV and RatioEY/SIV decrease as the 
IV tubing’s length increases. Future studies must reveal 
whether shorter tubing also requires a larger SFV propor-
tional to its volume.
Remarkably, SFVEY overall was larger than SFVMB. 
One explanation may be the higher initial concentration of 
EY (75 mg/L) compared to MB (40 mg/L). Another expla-
nation may be that EY may adhere more to the IV tubing 
wall than MB, so that its dispersion is not only caused by 
laminar flow but also by interaction of the solute with the 
tubing wall. However, this theory requires further study. It 
is also possible that this difference was (in part) caused by 
the layout of the experimental setup (Figure 1b). EY was 
connected to a three-way stopcock that is more distal from 
the fraction collector than the three-way stopcock to which 
MB is connected. The distance from the stopcock to the 
fraction collector was slightly larger for EY than for MB. 
The mean difference between SFVEY and SFVMB was 
0.6 mL, which is a little over twice the internal volume of 
a three-way stopcock (0.26 mL). Possibly SFVMB may 
have been larger than SFVEY if MB was connected to the 
stopcock distal from the fraction collector instead.
Guiffant et al.21 found that pulsed (turbulent) flow 
induced by repeated boluses was more effective in clearing 
proteins from a catheter than continuous (laminar) flow. 
Ferroni et al.22 found similar results when the goal was to 
reduce bacterial colonization of IV catheters. Although we 
did not focus on flushing catheters in this study, it is pos-
sible that administering SF in a pulsed manner is also more 
effective in clearing IV tubing of drugs compared to the 
continuous flow as was studied. The volumes used in the 
studies performed by Guiffant et al.21 and Ferroni et al.22 
(10 mL in both studies) were high compared to our study, 
Doesburg et al. 7
especially considering the flushing volume relative to the 
internal volume of the catheter (0.14 mL) at a ratio of 71 to 
1. Considering a patient’s fluid restrictions, administering 
a relative equivalent of 142 mL of SF in 2 mL of tubing 
would be highly undesirable.9,10
In this study, a concentration of 2% of the original con-
centration was considered sufficiently low to prevent a 
chemical reaction between the drug solutions in the IV 
tubing. It must be noted that sampling took place at the end 
of the IV tube, hence a negligible concentration can be 
expected in IV tubing segments distal from the patient. We 
therefore believe that in clinical practice no meaningful 
chemical interaction will occur at this cut-off point. In 
some cases a lower cut-off point may be desired, however 
this would require a larger SFV. This could be relevant to 
patients with a limited fluid intake regimen. Samples col-
lected using the fraction collector were relatively large 
(0.67 mL). If it was possible to use a smaller sample vol-
ume, this would yield more data points and therefore a 
more accurate representation of the concentration courses 
and calculation of the corresponding flushing volumes. A 
possible concern is whether the dyes used in this study 
properly reflected the behavior of IV solutions that are 
used in clinical practice, while also providing sufficient 
discrimination when measured analytically. MB and EY 
are soluble in both NS and G5, and can be measured using 
UV-Vis spectrophotometry. The UV spectra of MB and EY 
do not interfere with each other, allowing for good dis-
crimination. Hence, we believe that MB and EY serve as 
suitable models for IV drugs in this experimental setting.
For drugs such as insulin that are known to interact and 
even adhere to the tubing wall, larger SFVs may be 
required. The same may hold for highly viscous drug solu-
tions.3,4,23 For future studies we recommend comparing 
SFVs for such drugs or drug solutions. We did not study 
the adsorption of MB or EY on the tubing, however some 
degree of adsorption is likely as it is known MB can adsorb 
onto polymer material.24 The impact of adsorption on our 
results will require further study. In clinical practice the 
venous pressure in the patient provides a counter pressure 
to the administered IV solutions. This counter pressure 
may be different at the site of a central venous catheter 
compared with the site of a peripheral venous catheter. In 
our experimental setup there was no resistance at the end 
of the tubing, hence it is unknown to which extent such 
counter pressures would have affected our results. In this 
study the collected fractions were relatively large and there 
was a limited number of fractions that could be collected 
in one experimental run. This limited the number of data 
points we could acquire and also the number of different 
drug solutions that could fit in a single administration pro-
file. A future follow up on this study could use continuous 
diode-array detection (DAD), which would allow sam-
pling at a frequency of 1 Hz.25 This would also allow for 
longer and more complex administration profiles.
Conclusion
A larger volume of the IV tubing that is used by multiple 
drugs, requires a larger volume of SFV. Existing recom-
mendations to flush using a SFV that is at least twice the 
tubing’s priming volume were confirmed in profiles where 
2-m (2-mL) tubing was used. The ratio of SFV to the tub-
ing’s priming volume, decreases when the tubing is longer. 
Shorter tubing may require a larger SFV relative to its 
internal volume. The SFV was not affected by the choice 
of administration rate or solvent. G5 required a marginally 
smaller SFV than NS, however its clinical impact is 
debatable.
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Appendix 1
Flushing  The administration of a fluid to clear the dead 
space of IV tubing and catheters of its content.
Flushing 
volume  The volume of fluid required to successfully 
perform flushing.
Locking 
procedure  The practice of filling a catheter with a fluid 
for a period of time when the catheter is not 
used. Locking is performed to prevent cathe-
ter occlusion and thrombus formation, or to 
reduce bacterial colonization.
Priming volume  The volume of fluid required to fill the IV tub-
ing ensuring all air is removed from the 
tubing.
Shared infusion 
tubing  The part of the tubing that is shared by, and 
accessible to all IV fluids.
Shared infusion 
volume Volume of the shared infusion tubing.
Separator fluid  ntravenous (IV) solution that is used to sepa-
rate two incompatible solutions within the IV 
tubing.
Separator fluid 
volume  The volume of separator fluid required to 
safely separate two incompatible solutions.
Tubing  The collection of IV tubes and extension sets 
that connect an IV bag or syringe(s) to the 
patient’s IV access.
